Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / AMRX - Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment

AMRX - Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment

Amneal Pharmaceuticals Inc. Class A

  • Amneal Pharmaceuticals ( NYSE: AMRX ) has submitted a New Drug Application to the US FDA for IPX203 , carbidopa/levodopa (CD/LD) extended-release capsules for Parkinson’s disease.
  • The application is based on phase 3 data that showed more "good on" time compared to immediate-release CD/LD, even when IPX203 was dosed on average three times per day and immediate-release CD/LD was dosed on average five times.
  • Results also showed that those on IPX203 has significantly less "off" time compared to immediate-release CD/LD.
  • Seeking Alpha's Quant Rating views Amneal ( AMRX ) as a hold with high marks for valuation and profitability .

For further details see:

Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment
Stock Information
Company Name: Amneal Pharmaceuticals Inc. Class A
Stock Symbol: AMRX
Market: NASDAQ
Website: amneal.com
Menu
AMRX AMRX Quote AMRX Short AMRX News AMRX Articles AMRX Message Board
Get AMRX Alerts

News, Short Squeeze, Breakout and More Instantly...